-
Acadia's FDA Breakthrough Designation For Pimavanserin Draws Mixed Response
Thursday, October 5, 2017 - 2:20pm | 663Read More...ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock initially jumped above $41 per share on Thursday after the FDA granted Breakthrough Designation to the company’s dementia-related psychosis drug candidate Pimavanserin. However, the stock quickly reversed direction as the market digested the...
-
Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain
Friday, September 29, 2017 - 4:52pm | 482Read More...The Street reacted to Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE)’s positive Fragile X trial results with marked ambivalence. Investors propelled the stock 76 percent higher even as biotech and behavioral experts published critical reviews. Two analysts assigned Hold ratings, but Piper Jaffray...
-
The Street May Be Underappreciating Alder Biopharma's Phase 3 Data
Wednesday, June 28, 2017 - 3:51pm | 339Read More...Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) hit a new 52-week low Wednesday for the second consecutive day as many investors found fault with the company's results from a phase 3 trial of its Eptinezumab therapy for the treatment of migraines. Piper Jaffray's Charles Duncan, Ph.D....
-
Piper Jaffray Defends Alder Despite Stock Slump, Looks To What's Next In Migraine Management
Tuesday, June 27, 2017 - 12:11pm | 606Read More...Shares of Alder Biopharmaceuticals Inc (NASDAQ: ALDR) lost more than 20 percent on Tuesday and hit a new 52-week low of $13.80 despite reporting positive results for its late-stage migraine prevention drug called eptinezumab. Eptinezumab was successful in meeting the primary and key secondary...
-
Piper Jaffray Sees Strength In Geron After News Of Drug Development
Monday, December 7, 2015 - 11:29am | 267Read More...Piper Jaffray on Monday issued a company note on Geron Corporation (NASDAQ: GERN) after news of new drug developments at the ASH 2015 conference. Piper Jaffray rates Geron as Overweight and raised the company's price target from $5.00 to $10.00. Analysts Charles Duncan and Sarah Weber wrote...
-
On Wall Street, Questions Remain For Conatus Pharma
Friday, September 25, 2015 - 9:05am | 588Read More...Shares of Conatus Pharmaceuticals Inc (NASDAQ: CNAT) were higher by nearly 5 percent on Thursday, although shares initially surged higher by more than 30 percent following the announcement on Wednesday. Conatus announced results from its Phase II study of emricasan in 22 Portal Hypertension...
-
Acadia Pharma May No Longer Be A Buy Ahead Of NDA Filing
Friday, August 7, 2015 - 1:27pm | 277Read More...Piper Jaffray analyst Charles Duncan downgraded ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) from Overweight to Neutral, noting that the "next steps may be more challenging." At the same time, the analyst updated his price target to $48 from $39 prior. Duncan said that he is also...
-
Why Piper Jaffray's Charles Duncan Still Likes Catalyst Pharmaceuticals
Wednesday, February 18, 2015 - 11:15am | 653Read More...Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) is a company who develops therapeutic solutions for rare diseases. The company recently closed a previously announced public offering on February 9, netting approximately $3.25 a share, or a total of $34.7 million through the sale of 11.5...
-
Shares of Vivus Fall +10% Following Piper Jaffray's Downgrade
Thursday, April 3, 2014 - 1:03pm | 209Read More...Shares of VIVUS (NASDAQ: VVUS) respond to Piper Jaffray analyst Charles Duncan's downgrade from Neutral to Underweight and price target decrease to $3.00. Despite an improving anti-obesity market outlook in the U.S., Duncan reported that the macro-dynamics have not translated into gains for Qsymia...
-
Geron Revealed Positive Imetelstat Results Amidst Data Concerns
Thursday, November 7, 2013 - 2:10pm | 253Read More...Geron (NASDAQ: GERN) revealed positive results from Imetelstat data this morning. Geron published that Imetelstat, a drug used to treat myelofibrosis, had an overall response rate of 44 percent. Further, the company wrote, “Among 13 patients with leukocytosis, 10 (77 percent) normalized their...
